Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Feedback ( (GB:FDBK) ) just unveiled an announcement.
Feedback plc, the UK clinical infrastructure specialist behind the Bleepa digital collaboration platform, targets productivity gains in health and care by integrating systems, enabling secure information sharing and supporting the shift from hospital to community-based care. Its scalable SaaS model underpins growth opportunities across domestic and international healthcare markets, with a particular focus on the NHS and pathway-based services.
The company reports that a central NHS decision on a potential widescale Bleepa rollout has been delayed by at least six to nine months, but ongoing discussions remain positive and could align with new frontline digitisation funding expected in the 2026/27 NHS financial year. In the meantime, NHS England has extended Bleepa licences at Queen Victoria Hospital, expanded pathway work in Sussex and renewed a contract with Northern Care Alliance, while Feedback exits a photocapture deal to concentrate resources on higher-value Bleepa pathways, maintains active engagement with national NHS stakeholders and manages cash to provide runway through mid-2027.
Spark’s Take on FDBK Stock
According to Spark, TipRanks’ AI Analyst, FDBK is a Neutral.
The score is held down primarily by deteriorating financial performance (sharp revenue decline, very large/worsening losses, and ongoing cash burn), partially offset by a debt-free balance sheet. Technicals add modest support due to an upward trend, but extremely overbought signals raise near-term risk. Valuation provides limited support given negative earnings and no dividend yield data.
To see Spark’s full report on FDBK stock, click here.
More about Feedback
Feedback plc is a UK-listed clinical infrastructure specialist focused on unlocking productivity in health and care through digital connectivity and asynchronous collaboration. Its flagship product, Bleepa, is an award-winning SaaS collaboration platform that connects clinical systems, supports digital patient pathways and enables more efficient, community-based care for public and private healthcare providers, including the NHS.
Average Trading Volume: 98,638
Technical Sentiment Signal: Sell
Current Market Cap: £5.41M
For an in-depth examination of FDBK stock, go to TipRanks’ Overview page.